Literature DB >> 9788592

Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia.

M Esteller1, P G Corn, J M Urena, E Gabrielson, S B Baylin, J G Herman.   

Abstract

Glutathione S-transferases (GSTs) are a family of isoenzymes that play an important role in protecting cells from cytotoxic and carcinogenic agents. The pi-class GST has been associated with preneoplastic and neoplastic changes. Recently, it has been reported that regulatory sequences near the GSTP1 gene, which encodes the human pi-class GST, are commonly hypermethylated in prostatic carcinomas. In the present study, we studied more than 300 primary human tumors originating in other organs for aberrant methylation of GSTP1 using methylation-specific PCR. GSTP1 hypermethylation was most frequent in breast and renal carcinoma, showing aberrant methylation in 30 and 20% of the cases, respectively. Other tumor types showed promoter methylation only rarely or not at all. Hypermethylation of GSTP1 was associated with loss of expression demonstrated by immunohistochemistry. Our results suggest that aberrant methylation of GSTP1 may contribute to the carcinogenetic process in breast and renal carcinomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9788592

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  73 in total

Review 1.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

Review 2.  Epigenetics of kidney cancer and bladder cancer.

Authors:  Amanda M Hoffman; Paul Cairns
Journal:  Epigenomics       Date:  2011-02       Impact factor: 4.778

3.  Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients.

Authors:  Yoon Hee Cho; Jing Shen; Marilie D Gammon; Yu-Jing Zhang; Qiao Wang; Karina Gonzalez; Xinran Xu; Patrick T Bradshaw; Susan L Teitelbaum; Gail Garbowski; Hanina Hibshoosh; Alfred I Neugut; Jia Chen; Regina M Santella
Journal:  Breast Cancer Res Treat       Date:  2011-08-12       Impact factor: 4.872

4.  Polycyclic aromatic hydrocarbon (PAH)-DNA adducts and breast cancer: modification by gene promoter methylation in a population-based study.

Authors:  Alexandra J White; Jia Chen; Lauren E McCullough; Xinran Xu; Yoon Hee Cho; Susan L Teitelbaum; Alfred I Neugut; Mary Beth Terry; Hanina Hibshoosh; Regina M Santella; Marilie D Gammon
Journal:  Cancer Causes Control       Date:  2015-09-25       Impact factor: 2.506

5.  DNA hypermethylation profiles in squamous cell carcinoma of the vulva.

Authors:  Josena K Stephen; Kang Mei Chen; Misa Raitanen; Seija Grénman; Maria J Worsham
Journal:  Int J Gynecol Pathol       Date:  2009-01       Impact factor: 2.762

6.  Glutathione s-transferase p1: gene sequence variation and functional genomic studies.

Authors:  Ann M Moyer; Oreste E Salavaggione; Tse-Yu Wu; Irene Moon; Bruce W Eckloff; Michelle A T Hildebrandt; Daniel J Schaid; Eric D Wieben; Richard M Weinshilboum
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

Review 7.  Beyond genetics--the emerging role of epigenetic changes in hematopoietic malignancies.

Authors:  Oliver Galm; Manel Esteller
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

Review 8.  Epigenomics and breast cancer.

Authors:  Pang-Kuo Lo; Saraswati Sukumar
Journal:  Pharmacogenomics       Date:  2008-12       Impact factor: 2.533

9.  GSTP1 promoter hypermethylation is an early event in breast carcinogenesis.

Authors:  Ji Shin Lee
Journal:  Virchows Arch       Date:  2007-05-04       Impact factor: 4.064

10.  DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response.

Authors:  Emelyne Dejeux; Jo Anders Rønneberg; Hiroko Solvang; Ida Bukholm; Stephanie Geisler; Turid Aas; Ivo G Gut; Anne-Lise Børresen-Dale; Per Eystein Lønning; Vessela N Kristensen; Jörg Tost
Journal:  Mol Cancer       Date:  2010-03-25       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.